Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01796665
Recruitment Status : Completed
First Posted : February 22, 2013
Results First Posted : January 20, 2021
Last Update Posted : October 22, 2021
Information provided by (Responsible Party):
Padagis LLC

Brief Summary:
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to the already marketed formulation, Acanya gel in patients with acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Drug: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% Drug: Acanya Gel Drug: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
Study Start Date : February 2012
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Experimental: Test product
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
Drug: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%
Other Name: Test product

Active Comparator: Reference product
Acanya Gel applied to the affected areas of the face once daily.
Drug: Acanya Gel
Other Name: Reference product

Placebo Comparator: Placebo product
Placebo of the Test product applied to the affected areas of the face once daily.
Drug: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product
Other Name: Placebo product

Primary Outcome Measures :
  1. Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count [ Time Frame: Baseline to week 12 ]
    Per protocol population

  2. Mean Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Count [ Time Frame: Baseline to week 12 ]

Secondary Outcome Measures :
  1. Clinical Success on Investigator's Global Evaluation [ Time Frame: Baseline to week 12 ]
    Percentage of subjects with a clinical response of "success", defined as an IGA score that is at least 2 grades less than the baseline assessment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject and/or parent or legally authorized representative must sign an Institutional Review Board (IRB) approved written informed consent/assent.
  2. Male or female, 12 to 40 years of age, inclusive.
  3. Definite clinical diagnosis of facial acne vulgaris with an inflammatory lesion (papules and pustules) count between 20 and 50 and a non-inflammatory (open and closed comedones) lesion count between 25 and 100 and no more than 2 nodulocystic lesions (i.e., nodules and cysts) including those present on the nose.
  4. Baseline Investigator's Global Assessment Score of 3 (moderate severity) or 4 (severe) on a severity scale of 0 to 4.
  5. Willing and able to understand and comply with the requirements of the study, apply the medication as instructed, refrain from use of all other topical acne medication or topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and are able to complete the study.
  6. In general good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
  7. Females of childbearing potential (excluding women who are surgically sterilized or post menopausal for at least 2 years), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: Oral Contraceptives, Contraceptive patches, Contraceptive Injection (Depo-Provera), Contraceptive Implant (Implanon), Vaginal Contraceptive (Nuva-Ring), IUD, hormonal IUD (Mirena); double-barrier methods (e.g. condom and spermicide) and abstinence with a documented second acceptable method of birth control should subject become sexually active. A sterile sexual partner is not considered an adequate form of birth control. Subjects entering the trial that are on hormonal contraceptives must have been on this method for at least 3 months (90 days) prior to the trial and continue the method for the duration of the trial. Subjects who had used hormonal contraception and stopped must have stopped no less than 3 months (90 days) prior to baseline.

Exclusion Criteria:

  1. Pregnant, breast feeding, or planning a pregnancy within the study participation period.
  2. More than 2 facial nodulocystic lesions (i.e. nodules and cysts).
  3. Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.).
  4. Active cystic acne or Polycystic Ovarian Syndrome.
  5. History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis.
  6. Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents)
  7. Any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
  8. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
  9. History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide therapy.
  10. Use of systemic Clindamycin products 4 weeks prior to baseline or throughout the study.
  11. History of hypersensitivity or allergy to Clindamycin Phosphate, benzoyl peroxide and/or any ingredient in the study medication.
  12. Use within 6 months prior to baseline or during the study of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  13. Use within 30 days prior to baseline or during the study of therapeutic vitamin D supplement (daily multivitamins with total 800IU Vitamin D are allowed).
  14. Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids; Vitamin B12, etc as part of a multivitamin regimen is allowed).
  15. Start or change of dose of hormonal treatment (oral, implanted, topical contraceptives and androgens) 3 months prior to base-line or throughout the study. Use of such therapy must remain constant during the study.
  16. Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study (other than study supplied cleanser and lotion).
  17. Use within 30 days prior to baseline or during the study of 1) systemic steroids*, 2) systemic (e.g., oral or injectable) antibiotics, 3) systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or 4) systemic anti-inflammatory or immunosuppressive agents**. (*Intranasal and inhaled corticosteroids do not require a washout and may be used throughout the study if at a stable and standard dose.)**Subjects may use Acetaminophen for pain relief, as needed throughout the study).
  18. Use within 14 days prior to baseline or during the study of 1) topical steroids, 2) topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl peroxide, retinoids, azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.) including OTC preparations 4) benzoyl peroxide, 5) topical anti-inflammatory agents, or 6) topical antibiotics.
  19. Use on the face within 30 days prior to baseline or during the study of 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
  20. Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or triclosan) within 2 weeks of study start and throughout the study.
  21. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
  22. Use of Spironolactone for 4 weeks prior to baseline visit and throughout the study period is prohibited.
  23. Use of Antipruritics, including antihistamines within 24 hours of all study visits (Visit 1 through Visit 4).
  24. Participation in any clinical study involving an investigational product or device in the 4 weeks prior to study entry or throughout the study.
  25. Previous enrollment in this current study.
  26. Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week prior to enrollment and throughout the study.
  Study Documents (Full-Text)

Documents provided by Padagis LLC:
Study Protocol  [PDF] February 9, 2012
Statistical Analysis Plan  [PDF] February 9, 2012

Layout table for additonal information
Responsible Party: Padagis LLC Identifier: NCT01796665    
Other Study ID Numbers: PRG-NY-12-005
First Posted: February 22, 2013    Key Record Dates
Results First Posted: January 20, 2021
Last Update Posted: October 22, 2021
Last Verified: October 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Clindamycin palmitate
Clindamycin phosphate
Benzoyl Peroxide
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents